Interferon gamma-1a biosimilar (Shionogi)

干扰素γ-1a生物类似药（盐野义）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInterferon gamma-1a biosimilar (Shionogi)
Drug Alias NameImunomax干扰素γ-1a生物仿制药（盐野义）Interferon gamma-1a biosimilarImunomax-γS-6810
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterferon gamma receptor stimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsImmunostimulants
TargetsInterferon gamma receptor
Therapy Area/IndicationsMyocardial InfarctionCarcinoma, Renal CellMycosis Fungoides +[4] 
Global Approved IndicationsMyocardial InfarctionCarcinoma, Renal CellMycosis Fungoides +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date1989/09/29
Country/TerritoryJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesShionogi & Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShionogi & Co Ltd
Inactive CompaniesN/A
Active IndicationsMyocardial InfarctionCarcinoma, Renal CellMycosis Fungoides +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AB03
Related LinksN/A